Method of treating renal cell carcinoma using activated mononuclear cells, renal tumor antigen and cimetidine
US5192537A · kind A · utility
24Cited by
4References
5Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Aug 19, 1991 |
| Grant date | Mar 9, 1993 |
| Priority date | — |
| Expiry date | Aug 19, 2011 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2502/11
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Immunoreactive cells sensitized for an antigenic marker associated with a malignant tumor are prepared in vitro by collecting the tumor patient's own mononuclear cells, depleting suppressor T-cells, suspending the mononuclear cells with serum, preferably autologous, and culturing the cells under conditions to activate and immunize the patient's mononuclear cells against the patient's tumor. Methods of treatment and immunized cells in pharmaceutical presentations are described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.